SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts

Matilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J Lannutti, Katti A Jessen, Tiziana Vaisitti, Silvia Deaglio · 2026

Read SLV‐404, an anti‐RYK antibody–drug conjugate, is effective in Richter transformation patient‐derived xenografts by Matilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J Lannutti, Katti A Jessen, Tiziana Vaisitti, Silvia Deaglio (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13628558.txt.

Description

Matilde Micillo and nine colleagues tested a new antibody-drug conjugate against Richter transformation, an aggressive lymphoma that erupts out of chronic lymphocytic leukaemia and answers poorly to standard chemotherapy. Their candidate, SLV-404, aims at RYK, a cell-surface protein found across many lymphomas yet absent from healthy blood cells.

The conjugate pairs an anti-RYK antibody with deruxtecan, a powerful drug that blocks an enzyme tumours need to copy DNA. In laboratory cultures and in patient-derived tumour grafts it triggered strong cancer cell death while sparing normal blood cells. Mice carrying such grafts lived significantly longer with much smaller tumour burdens, leading the authors to propose RYK as a fresh target for aggressive lymphoma therapy.

Catalog record

CREATORMatilde Micillo, Beatrice Pirajno, Francesco Edoardo Vallone, Victor Navarro‐Tableros, Elisabetta Bolli, Valentina Griggio, Brian J Lannutti, Katti A Jessen, Tiziana Vaisitti, Silvia Deaglio
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13628558

Browse the full library · About the Tower of Babel